Stephen T. Isaacs Sells 7,949 Shares of Aduro BioTech Inc (ADRO) Stock

Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 7,949 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $7.95, for a total transaction of $63,194.55. Following the completion of the sale, the insider now owns 213,695 shares of the company’s stock, valued at $1,698,875.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Aduro BioTech Inc (ADRO) opened at $6.75 on Wednesday. Aduro BioTech Inc has a one year low of $6.01 and a one year high of $14.05. The firm has a market cap of $552.72, a price-to-earnings ratio of -4.96 and a beta of 3.52.

Aduro BioTech (NASDAQ:ADRO) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.54) EPS. analysts forecast that Aduro BioTech Inc will post -1.28 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. bought a new stake in shares of Aduro BioTech in the 2nd quarter worth about $408,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Aduro BioTech by 13.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 165,338 shares of the biotechnology company’s stock worth $1,885,000 after buying an additional 20,226 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Aduro BioTech by 13.7% in the 2nd quarter. Rhumbline Advisers now owns 44,889 shares of the biotechnology company’s stock worth $512,000 after buying an additional 5,410 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Aduro BioTech in the 2nd quarter worth about $353,000. Finally, Legal & General Group Plc increased its holdings in shares of Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares during the last quarter. Institutional investors and hedge funds own 45.19% of the company’s stock.

Several brokerages recently weighed in on ADRO. William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Aduro BioTech in a research report on Wednesday, September 27th. Oppenheimer started coverage on shares of Aduro BioTech in a research report on Monday, October 30th. They issued a “buy” rating and a $15.00 target price for the company. BidaskClub downgraded shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $17.71.

WARNING: “Stephen T. Isaacs Sells 7,949 Shares of Aduro BioTech Inc (ADRO) Stock” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/aduro-biotech-inc-adro-insider-stephen-t-isaacs-sells-7949-shares-of-stock/1822101.html.

Aduro BioTech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.